Tumor vaccines: A role in preventing recurrence in melanoma?

American Journal of Clinical Dermatology

Volumn 3, Issue 9, 2002, Pages 609-616

  Sabel, Michael S ^a,b   Sondak, Vernon K ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b 3304 Cancer Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIIDIOTYPIC ANTIBODY; BCG VACCINE; CANCER VACCINE; CYTOKINE; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; GANGLIOSIDE; GANGLIOSIDE GM2; GANGLIOSIDE VACCINE; GLYCOPROTEIN GP 100; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MELACINE; MELAN A; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; PHOSPHORYL LIPID A; TUMOR CELL VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG; VACCINIA ONCOLYSATE; VIRUS ONCOLYSATE;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CELL CULTURE; CELL LINE; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; GRANULOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFLAMMATION; MELANOMA; PRIORITY JOURNAL; REVIEW; SKIN ABSCESS; TUMOR IMMUNITY;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNITY, CELLULAR; MELANOMA; NEOPLASM RECURRENCE, LOCAL; VACCINES, SUBUNIT;

EID: 0036917847     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203090-00003     Document Type: Review

References (81)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics 2001. CA Cancer J Clin 2001; 51: 15-36
2. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001; 19 (16): 3635-48
3. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17
4. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-80
5. Leong SPL. Immunotherapy of malignant melanoma. Surg Clin North Am 1996; 76 (6): 1355-81
6. Wolchok JD, Livingston PO. Vaccines for melanoma: Translating basic immunology into new therapies. Lancet Oncol 2001; II: 205-11
7. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: Lessons learned from melanoma. Curr Opin Immunol 2001; 13 (2): 134-40
8. Jones RC, Kelley M, Gupta RK, et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model. Ann Surg Oncol 1996; 3: 437-45
9. Hsueh EC, Gupta RK, Qi K, et al. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998; 16: 2913-20
10. Van Der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7
11. Weber J. Melanoma peptide vaccines: From preclinical background to clinical trials. Curr Oncol Rep 2000; 2 (1): 38-47
12. McGee JM, Price JA, Mayes JS, et al. Melanoma vaccines as a therapeutic option. South Med J 1999: 92 (7): 698-704
13. Lee P, Wang F, Kuniyoshi J, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001; 19 (18): 3836-47
14. Menoret A, Chandawarkar R. Heat shock protein-based anticancer immunotherapy: An idea whose time has come. Semin Oncol 1998; 25: 654-60
15. Maeuer MJ, Storkus WJ, Kirkwood JM, et al. New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 1996; 6: 11-24
16. Byrstyn JC, Ortaz R, Roses D, et al. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage III malignant melanoma. Cancer 1992; 69: 1157-64
17. McCulloch PB, Dent PB, Blajchman M, et al. Recurrent malignant melanoma: Effect of adjuvant immunotherapy on survival. Can Med Assoc J 1977; 117: 33-6
18. Berd D, Maguire HC, Nathan FN, et al. Autologous, DNP-modified vaccine as post-surgical adjuvant treatment of stages III and IV melanoma [abstract]. Proc Am Soc Clin Oncol 1996; 15: 554
19. Berd D, Maguire Jr HC, Schuchter LM, et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997; 15 (6): 2359-70
20. Berd D, Kairys J, Dunton C, et al. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol 1998; 25 (6): 646-53
21. McIllmurray MB, Embleton MJ, Reeves WG, et al. Controlled trial of active immunotherapy in management of stage IIB malignant melanoma. BMJ 1977; 1 (6060): 540-2
22. McIllmurray MB, Reeves WG, Langman MJS, et al. Active immunotherapy in melanoma [letter]. BMJ 1978; 1 (6112): 579
23. Aranha GV, McKhann CF, Grage TB, et al. Adjuvant immunotherapy of malignant melanoma. Cancer 1979; 43: 1297-303
24. Takahashi T, Johnson TD, Nishinaka Y, et al. IgM anti-ganglioside antibodies induced by melanoma cell vaccine corelate with survival of melanoma patients. J Invest Dermatol 1999; 112: 205-9
25. Hsueh EC, Gupta RK, Qi K, et al. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998; 16: 2913-20
26. Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-82
27. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996; 46: 225-44
28. Chan AD, Morton DL. Active immunotherapy with allogeneic tumor cell vaccines: Present status. Semin Oncol 1998; 25: 611-22
29. Morton DL, Nizze A, Hoon D, et al. Improved survival of advanced stage IV melanoma following active immunotherapy: Correlation with immune response to melanoma vaccine [abstract]. Proc Am Soc Clin Oncol 1993; 12: 391
30. Hsueh EC, Nizze A, Essner R, et al. Adjuvant immunotherapy with polyvalent melanoma cell vaccine (PMCV) prolongs survival after complete resection of distant melanoma metastases [abstract]. Proc Am Soc Clin Oncol 1997; 16: 492
31. Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-82
32. Mitchell MS, Harel W, Kempf RA, et al. Active specific immunotherapy of melanoma. J Clin Oncol 1992; 10: 1158-64
33. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998; 25: 623-35
34. Mitchell MS, Harel W, Kan-Mitchell J, et al. Active specific immunotherapy of melanoma with allogeneic cell lysates: Rationale, results, and possible mechanisms of action. Ann N Y Acad Sci 1993; 690: 153-66
35. Mitchell MS, Von Eschen KB. Phase III trial of melacine melanoma theraccine vs combination chemotherapy in the treatment of stage IV melanoma [abstract]. Proc Am Soc Clin Oncol 1997; 16: 1778
36. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998; 25: 623-35
37. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002; 20 (8): 2058-66
38. Mitchell MS, Harel W, Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 1992; 10: 1158-64
39. Sosman JA, Unger JM, Liu PY, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. J Clin Oncol 2002; 20 (8): 2067-75
40. Tai T, Cahan LD, Tsuchida T, et al. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 1994; 35: 607-12
41. Irie RF, Matsuki T, Morton DL. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1989; 1: 786-7
42. Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986; 83: 8694-8
43. Livingston PO, Ritter G, Srivastava P, et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989; 49: 7045-50
44. Takahashi T, Johnson TD, Nishinaka Y, et al. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 1999 Feb; 112 (2): 205-9
45. Helling F, Zhang S, Shang A, et al. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995; 55: 2783-8
46. Chapman BP, Morissey DM, Panageas KS, et al. Induction of antibodies against GM2 ganglioside by immunising melanoma patients using GM2-KLH + QS21 vaccine: A dose-response study. Clin Cancer Res 2000; 6: 874-9
47. Cassel WA, Murray DR, Phillips HS. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 1983; 52: 856-60
48. Wallack MK, McNally KR, Leftheriotis E, et al. A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. Cancer 1986; 57 (3): 649-55
49. Hersey P, Coates P, McCarthy WH. Active immunotherapy following surgical removal of high risk melanoma: Present status and future prospects. Proceedings of the 8th Annual Scientific Meeting of the Society for Biological Therapy: Biological Therapy of Cancer-VIII SBT93; 1993 Nov 10-14; Nashville (TN), 24
50. Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187 (1): 69-77
51. Hersey P. Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann NY Acad Sci 1993; 690: 167-77
52. Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J Surg 1992; 16: 251-60
53. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997; 88: 21-39
54. Sun Y, Jurgovsky K, Moller P, et al. Vaccination with IL-12 gene modified autologous melanoma cells: Preclinical results and a first clinical phase I study. Gene Ther 1998; 5: 481-90
55. Moller P, Sun Y, Dorbic T, et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study. Br J Cancer 1998; 77: 1907-16
56. Abdel-Wahab Z, Weltz C, Hester D, et al. A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells: Monitoring the humoral immune response. Cancer 1997; 80: 401-12
57. Arienti F, Sule-Soso J, Belli F, et al. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 1996; 7: 1955-63
58. Belli F, Arienti F, Sule-Soso J, et al. Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability. Cancer Immunol Immunother 1997; 44: 197-203
59. Dranoff G, Soiffer R, Lynct T, et al. A phase I study of vaccination with autologous irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1997; 8: 111-23
60. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulyocyte macrophage colony stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 85: 13141-6
61. Ellern KA, O'Rourke MG, Johnson GR, et al. A case report: Immune responses and clinical course of the first human use of GMCSF transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997; 44: 10-20
62. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumour cell engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43
63. Nouri-Shirazi M, Bachereau J, Jay J, et al. Dendritic cell based tumor vaccines. Immunol Lett 2000; 74 (1): 5-10
64. Thumer B, Haendle I, Roder C, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T-cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190 (11): 1669-78
65. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4 (3): 328-32
66. Bodey B, Bodey Jr B, Siegal SE, et al. Failure of cancer vaccines: The significant limitations of this approach to immunotherapy. Anticancer Res 2000; 20 (4): 2665-76
67. Lindenmann J. Speculations on idiotypes of homobodies. Ann Immunol Paris 1973; 124: 171-84
68. Jerne NK. Towards a network theory of the immune system. Ann Immunol Paris 1974; 125C: 373-89
69. Chatterjee MB, Baral N, Chatterjee SK, et al. Cancer vaccines: Single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer Immunol Immunother 2000; 49: 133-41
70. Bhattacharya-Chatterjee M, Kohler H. Anti-idiotype tumor vaccines. Adv Exp Med Biol 1990; 251: 113-28
71. Chatterjee MB, Foon KA, Köhler H. Idiotypic antibody immunotherapy of cancer. Cancer Immunol Immunother 1994; 38: 75-82
72. Mittelman A, Wang X, Matsumoto K, et al. Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 1995; 14: 175-81
73. Saleh MN, Stapleton JD, Khazaeli MB, et al. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J Immunol 1993; 151: 3390-8
74. McCaffery M, Yao TJ, Williams L, et al. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 1996; 2: 679-86
75. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA. Anti-idiotype vaccine against cancer. Immunol Lett 2000; 74: 51-8
76. Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 2000; 18 (2): 376-84
77. Fu TM, Ulmer JB, Caulfield MJ. Priming of cytotoxic T lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 1997; 3: 362-71
78. Ulmer JB, Deck RR, DeWitt CM, et al. Expression of a viral protein by muscle cells in vivo induces protective cell-mediated immunity. Vaccine 1997; 15: 839-41
79. Klinman DM, Yi AK, Beuacage SL, et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon gamma. Proc Natl Acad Sci USA 1996; 93: 2879-83
80. Yee C, Riddell SR, Greenberg PD. In vivo tracking of tumor-specific T cells. Curr Opin Immunol 2001; 13: 141-6
81. Romero P, Cerottini JC, Waanders GA. Novel methods to monitor antigen-specific cytotoxic T-cells responses in cancer immunotherapy. Mol Med Today 1998; 4 (7): 305-11